Quzyttir
Total Payments
$261,586
Transactions
2,363
Doctors
1,398
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $21,908 | 657 | 483 |
| 2023 | $19,269 | 751 | 477 |
| 2022 | $24,930 | 672 | 484 |
| 2021 | $195,479 | 283 | 210 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $149,917 | 14 | 57.3% |
| Food and Beverage | $58,038 | 2,307 | 22.2% |
| Consulting Fee | $53,389 | 38 | 20.4% |
| Education | $242.00 | 4 | 0.1% |
Payments by Type
Research
$149,917
14 transactions
General
$111,669
2,349 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2 Exploratory Study of Intravenous Quzyttir (Cetirizine HCl Injection) Versus IV Diphenhydramine in the Prevention of Hypersesitivity Infusion Reactions | TerSera Therapeutics LLC | $149,917 | 0 |
Top Doctors Receiving Payments for Quzyttir
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Rancho Mirage, CA | $149,981 | 17 |
| , M.D | Allergy & Immunology | Roswell, GA | $6,106 | 4 |
| , M.D | Surgical Oncology | Spring Branch, TX | $6,100 | 2 |
| , M.D | Internal Medicine | Studio City, CA | $4,914 | 2 |
| , M.D | Hematology & Oncology | Lexington, KY | $3,492 | 1 |
| , MD | Medical Oncology | Houston, TX | $2,619 | 3 |
| , M.D | Internal Medicine | Houston, TX | $2,350 | 1 |
| , MD | Hematology & Oncology | Santa Rosa, CA | $1,887 | 1 |
| , MD | Internal Medicine | Boston, MA | $1,746 | 1 |
| , MD, MHA, FRCPC | Hematology & Oncology | Portland, OR | $1,746 | 1 |
| , M.D | Internal Medicine | Rochester, MN | $1,746 | 1 |
| , MD | Medical Oncology | Tampa, FL | $1,746 | 1 |
| , M.D | Medical Oncology | Philadelphia, PA | $1,404 | 1 |
| , M.D | Hematology & Oncology | Murray, UT | $1,404 | 1 |
| , MD | Medical Oncology | Nashville, TN | $1,404 | 1 |
| , M.D | Hematology & Oncology | Salt Lake City, UT | $1,404 | 1 |
| , MD | Pediatric Hematology-Oncology | Birmingham, AL | $1,392 | 1 |
| , MD | Pediatrics | Hartford, CT | $1,318 | 1 |
| , MD | Neurology | Columbia, MO | $1,175 | 3 |
| , M.D | Emergency Medicine | Providence, RI | $1,120 | 1 |
| , MD | Pediatrics | Washington, DC | $1,110 | 1 |
| , MD | Hematology & Oncology | Farmington, CT | $1,110 | 1 |
| , M.D | Hematology & Oncology | Atlanta, GA | $1,110 | 1 |
| , M.D | Internal Medicine | Richmond, VA | $953.49 | 2 |
| , M.D | Internal Medicine | San Diego, CA | $924.85 | 4 |
Ad
Manufacturing Companies
- TerSera Therapeutics LLC $261,586
Product Information
- Type Drug
- Total Payments $261,586
- Total Doctors 1,398
- Transactions 2,363
About Quzyttir
Quzyttir is a drug associated with $261,586 in payments to 1,398 healthcare providers, recorded across 2,363 transactions in the CMS Open Payments database. The primary manufacturer is TerSera Therapeutics LLC.
Payment data is available from 2021 to 2024. In 2024, $21,908 was paid across 657 transactions to 483 doctors.
The most common payment nature for Quzyttir is "Unspecified" ($149,917, 57.3% of total).
Quzyttir is associated with 1 research study, including "A Phase 2 Exploratory Study of Intravenous Quzyttir (Cetirizine HCl Injection) Versus IV Diphenhydramine in the Prevention of Hypersesitivity Infusion Reactions" ($149,917).